Cardiovascular diseases are the number one cause of death globally, attributing to an estimated 17.7 million deaths in 2015; approximately 31% of all global deaths.
| INTRODUC TI ON
Cardiovascular diseases are the number one cause of death globally, attributing to an estimated 17.7 million deaths in 2015; approximately 31% of all global deaths. 1 Melatonin has been increasingly recognized in various cardiovascular diseases. Specifically, reduced production and secretion of melatonin, and its metabolite 6-sulphatoxymelatonin, are associated with chronic heart failure, coronary heart diseases, angina, congestive heart failure, myo- is not surprising that recent research has emerged highlighting a key role of melatonin in blood pressure regulation. In animal and human studies alike, melatonin has been substantiated as an effective and safe anti-hypertensive agent. However, the precise mechanism(s) by which melatonin elicits its hypotensive effects in humans require further investigation. This review focuses on melatonin, its role within the cardiovascular system and the emerging implications for its use as an adjunct anti-hypertensive agent. Lastly, this review discusses the current thinking on potential mechanisms behind the hypotensive effects of melatonin, including: endothelium-dependent vasodilation, anti-oxidant defence mechanisms and sympatho-vagal autonomic regulation.
PubMed, EMBASE and Scopus were searched with the following key words: melatonin (drug therapy), melatonin (therapy), melatonin receptors, blood pressure, hypertension, nocturnal hypertension, cardiovascular, cardiovascular disease, sleep, autonomic nervous system, autonomic failure. For more extensive discussion of melatonin, its receptors and their functionalities in other systems, see reviews. there is a cascade of activation starting at the suprachiasmatic nucleus and ending at the pineal gland resulting in increased melatonin production and secretion. 5 The neuronal pathway mediating production and secretion of melatonin is as follows:
1. Light stimulates the retina which activates the suprachiasmatic nuclei (SCN)
Activation of the SCN inhibits the paraventricular nucleus (PVN)
3. Paraventricular nucleus projects to the sympathetic intermediolateral (IML) nucleus in the T1-T3 segments of the spinal cord
4.
Intermediolateral projects to the superior cervical ganglia which projects to the pineal gland to increase melatonin production and secretion ( Figure 1 ).
Light induces sympatho-excitation and vagal suppression, a response that is mediated through the SCN. 6 When light is present, there is inhibition of the PVN by the SCN thereby inhibiting the remainder of the signal cascade. In contrast, in low light conditions there is disinhibition of the PVN allowing the remainder of the neuronal activation pathway to continue. 5 Melatonin is produced and secreted by the pineal gland; where it can bind to structures within the brain, however, it is also released into the peripheral blood and cerebrospinal fluid where it binds to its receptors and influences cardiovascular regulation.
| Melatonin receptors
In humans, three types of melatonin receptors (MT) have been iden- Melatonin plays a key role in circadian rhythmicity and seasonal cycling. Therefore, it is not surprising that a high density of melatonin receptors have been identified in the central nervous system including, but not limited to the: pituitary, hypothalamus, F I G U R E 1 Neural pathway mediating melatonin production and secretion. In the presence of light, the suprachiasmatic nucleus inhibits the paraventricular nucleus (PVN), which indirectly inhibits melatonin production and secretion from the pineal gland. In the absence of light, or under low light conditions, there is disinhibition of the PVN, which in turn results in melatonin production and secretion suprachiasmatic nucleus, paraventricular nucleus, and hippocampus in the brains of rat, 13 
| Coronary heart disease (CHD)
In a study of 15 CHD patients vs healthy controls, night time serum melatonin concentrations were found to be more than 5× lower in CHD patients than in controls. 26 Similarly, in 16 patients with coronary artery disease (CAD), blood samples collected every 2 hours between 22:00 and 08:00 revealed that CAD patients secreted less melatonin at 2 am, 4 am, and 8 am compared to controls. 27 In 48 male CHD patients vs 18 matched controls, overnight urinary aMT6s levels were also significantly lower in the patient group. 28 Finally, in comparing urinary aMT6s levels in patients with stable vs unstable angina, coronary disease (CD) and healthy controls, patients with unstable angina had significantly lower nocturnal urinary aMT6s levels compared to both healthy controls and patients with stable angina.
In contrast, these lower levels were not significantly different from patients with CD. 29 The results suggest that low melatonin production is associated with higher risk of cardiac infarction and/or death, as is the case with unstable angina.
| Congestive heart failure (CHF)
A comparison of urinary aMT6s excretions in 33 patients with severe CHF against 146 healthy controls revealed significantly lower aMT6s excretions in CHF patients. Furthermore, there were no significant differences between chronic and acute CHF patients.
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Although the mechanisms to help explain reduced melatonin production in CHF remain to be fully elucidated, the authors proposed a multi-faceted interplay between melatonin production, sympathetic receptor activity and neuropeptide Y, a norepinephrine cotransmitter. In addition, the authors suggested a modulatory role of melatonin production via substances that are increased in CHF patients including: vasopressin, prostaglandins and calcitonin-gene related peptide. 
| ROLE OF MEL ATONIN IN B LOOD PRE SSURE REG UL ATION
Given the widespread distribution of melatonin receptors within the cardiovascular and nervous systems, it is not surprising that recent research has emerged highlighting a key role of melatonin in neurovascular blood pressure (BP) regulation. Currently, there are several pieces of scientific evidence supporting the role of melatonin in blood pressure regulation.
| Evidence in rodent models
Following pinealectomy in rats, there is evidence of vasoconstriction 32 with subsequent hypertension. [32] [33] [34] [35] Furthermore, the pinealectomy-induced hypertension was reversed through exogenous melatonin administration. 32, 35 Similarly, melatonin deficiency as a result of continuous light exposure (24 hours/d) prevented nocturnal rises in melatonin, which in turn elicited peripheral vasoconstriction, hypertension and a decrease in BP variability. 36, 37 In spontaneously hypertensive rats (SHR), exogenous melatonin administration ameliorated hypertension as evidenced by reductions in mean, systolic and diastolic BPs. Melatonin treatment in hypertensive models has also been associated with reduced interstitial renal inflammation as measured by infiltration of lymphocytes and macrophages, 38 enhanced endothelium-dependent vasodilation, 39 improved cerebral autoregulation, 40 sympathetic inhibition, 41 reduced catecholamine levels 41 and improved baroreflex responses. 42 In models of type 2 diabetes with insulin resistance hypertension 43 and hypertension in rats with metabolic syndrome, exogenous melatonin administration significantly ameliorated hypertension. 44 Moreover, the effects of melatonin and N-acetylcysteine (an antioxidant) in SHR with established hypertension found that both were able to improve nitric oxide (NO) pathways via enhanced NO synthase, but only melatonin was able to reduce blood pressure significantly. Moreover, melatonin lowered the vasoconstrictor response to phenylephrine in the femoral artery. 45 The study concluded, that while both melatonin and N-acetylcysteine were able to improve NO pathways, the observed therapeutic effects of melatonin on blood pressure were mediated through an alternative mechanism independent of NO pathways. Finally, in a direct comparison of melatonin and captopril, an ACE-inhibitor, melatonin ameliorated the increase in systolic blood pressure induced via continuous light exposure. 
| Evidence in healthy individuals
In humans, the role of exogenous melatonin in autonomic and BP regulation has been studied in both healthy and disease models.
Low doses of melatonin (1 mg) in both healthy men and women have elicited significant reductions in systolic, diastolic and mean BPs, significantly lowered noradrenaline (NA) levels, and decreased the pulsatility index of the internal carotid artery -a direct representation of impedance to blood flow suggestive of vasoconstriction. [48] [49] [50] [51] In similar studies, 2 mg of oral melatonin significantly reduced supine plasma NA and dopamine levels, decreased supine BP and increased parasympathetic parameters of heart rate variability. 52 Lastly, in response to an orthostatic challenge, a manoeuvre associated with increased sympathetic activity, 3 mg of oral melatonin significantly reduced the increase in sympathetic activity as measured through direct sympathetic measures using microneurography 53 (Table 1 ).
| Evidence in nocturnal hypertension
Sleep is responsible for many regulatory and homeostatic functions in human physiology. For example, abnormal sleep patterns and/or impaired quantity and quality, have been linked to increased body mass index/risk for obesity and increased risks of heart attack, stroke, cardiovascular disease and hypertension. 54 67 and is an independent predictor of cardiovascular events. 62, 68, 69 Reduced melatonin production and secretion throughout the night has been implicated in the pathogenesis of non-dipping, reverse dipping and nocturnal hypertension. 70 In a structured search of controlled trials, a total of 877 patients were classified as either dippers or non-dippers. The results of this study demonstrated that mean melatonin levels in the 'dipper' group was significantly higher compared to the non-dipper group (data in abstract form). 71 Similarly, patients with essential hypertension also revealed that non-dippers had a significantly blunted ratio of night:day concentrations of melatonin. 72 Obayashi et al, 73 also re- [74] [75] [76] [77] The results of these studies also provide evidence to support melatonin as a potential adjunct nocturnal anti-hypertensive agent (Table 1) . significantly increase NO and eNOS activity up to 24 hours posttreatment. 81 In vivo, the hypotensive effects of melatonin have been studied using both fast-(FR) and controlled-release (CR) melatonin in various dosages and across a wide array of treatment durations.
| Role as an anti-hypertensive agent
In a meta-analysis of eight studies (5 FR; 3 CR), totalling 344 study participants, CR melatonin was found to effectively lower nocturnal systolic (−6 mm Hg, P = .009) and diastolic (−2.6 mm Hg, P = .009) blood pressures. 77 Furthermore, Cagnacci et al, 82 found that 83%
of women studied had a mean nocturnal decline >10 mm Hg during melatonin treatment, and similarly, Grossman et al, 74 reported 58% of patients had a decrease >5 mm Hg with the most prominent drops between the hours of 2 and 5 am (Table 1) .
Overall, while these studies provide initial exciting evidence that provide preliminary support for melatonin as an effective adjunct anti-hypertensive agent, safe for use in humans, larger multicentred clinical trials should be accomplished. In addition, the mechanism(s)
by which melatonin regulates blood pressure reduction in humans has yet to be fully elucidated.
| MECHANIS MS OF MEL ATONIN IN B LOOD PRE SSURE REG UL ATI ON
Despite a large amount of evidence in support of vasodilation and hypotensive effects of melatonin, these results cannot be explained on the basis of receptor stimulation. As previously mentioned, melatonin receptors are linked to Gi-and Gq-receptor activation, which in turn leads to decreased levels of cAMP and increased levels of 
| Endothelium-dependent vasodilation
Two primary pathways by which melatonin is suggested to influence vasodilation include: direct calcium channel blocking and indirectly through endothelium-dependent increases in NO and cGMP. Satake et al 84 demonstrated an inhibitory effect of melatonin that was similar to that of verapamil suggesting melatonin has characteristics similar to that of a calcium channel blocker to attenuate vasoconstriction. In addition, the vasodilatory effects of melatonin were also, in part, endothelium-dependent and related to increased production of cGMP. 84 
| Anti-oxidant/free radical scavenger
Oxidative stress is involved in many pathophysiological conditions and has been tightly associated with hypertension. Reactive oxygen (ROS) and nitrogen species (RNS) can cause DNA damage and have potentially deleterious effects on cell function and integrity.
Anti-oxidant defence systems help limit the damage that occurs as a result of oxidative stress and free radicals. Melatonin scavenges several oxygen-derived reactive agents including hydroxyl radicals, F I G U R E 2 Mechanism for endothelium-dependent vasodilation mediated through melatonin. Ca2+, calcium; eNOS; cGMP, Cyclic guanosine monophosphate; endothelium nitric oxide synthase; MT2, melatonin type 2 receptor; NO, nitric oxide hydrogen peroxide, singlet oxygen and hypochlorous acid. Melatonin can also react with peroxynitrite anion and/or peroxynitrous acid to detoxify them. 90 The structure of melatonin is advantageous in that it is an amphiphilic molecule, and can therefore elicit its anti-oxidant effects in both lipid and aqueous environments. 91 Furthermore, enzymes such as catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH) help limit the formation of free radicals, and neutralize ones that have formed. In hypertensive models, 92 as well as clinically hypertensive populations, 93 where anti-oxidant reserves are shown to be reduced, melatonin administration significantly increases GSH, CAT and SOD levels. 42, 92, 94 Furthermore, the improvements in these anti-oxidative defences as a result of melatonin administration have also been associated with lower blood pressure and inhibition of the contractile responses to various contractile agents including phenylephrine and noradrenaline. 92 
| Central sympatho-vagal autonomic regulation
The presence or absence of light induces sympatho-vagal fluctuations that can in turn influence melatonin production and secretion.
Additionally, melatonin production inhibits sympathetic activity in a regulatory manner that is likely evoked through bi-directional pathways in the brain as well as through negative feedback inhibition in circumstances of high melatonin production. Ultimately, there appears to be an intricate relationship between melatonin and autonomic activity. Melatonin, the primary circadian hormone, plays a critical role in the measurable diurnal changes that occur in many physiological systems, including cardiovascular. Additionally, the same cardiovascular processes (ie, heart rate, blood pressure, etc.)
that are altered during an asleep vs awakened state are under the control of the autonomic nervous system (ANS). More specifically, the intricate balance between sympathetic and parasympathetic oscillations influence these haemodynamic fluctuations. During nonrapid eye movement (REM) sleep, parasympathetic predominance is observed as reflected through reduced sympathetic burst activity, blood pressures and heart rate. In contrast, REM sleep is associated with profound increases in sympathetic activation, at levels similar to that of an awakened state. [95] [96] [97] [98] Nocturnal sympatho-vagal imbalance, which in turn may influence melatonin production and secretion is suggested to be involved in the pathology of nocturnal hypertension and non-dipping BP patterns. 99, 100 This is supported by studies investigating sleep patterns in clinical populations of autonomic failure. Patients with pure autonomic failure and multiple system atrophy (MSA) with autonomic failure show impaired nocturnal blood pressure profiles. 101, 102 In contrast, MSA patients without autonomic failure express normal nocturnal dipping. 103 Furthermore, patients with autonomic failure acquire abnormal nocturnal blood pressure profiles independent of REM sleep disorders and other sleep abnormalities, suggesting the pattern of nocturnal dipping is associated with autonomic functioning and not sleep pathologies.
Lastly, nocturnal hypertension is associated with elevated sympathetic activation, increased levels of NA, sympatho-vagal imbalance and reduced production and secretion of melatonin. 76 Therefore, it
is not surprising that melatonin may elicit its hypotensive effects, in part, through regulation of central autonomic networks. 
| Sympathetic inhibition

106
In studies involving humans, changes in autonomic regulation have been measured through direct sympathetic nerve activity (via microneurography) and indirectly via circulating catecholamine levels, measures of heart rate variability and blood flow. In a group of healthy volunteers, melatonin significantly blunted the increase in sympathetic activity normally seen in response to baroreceptor unloading elicited through lower body negative pressure. 53 Similarly, in both a supine position and in response to an orthostatic challenge, melatonin administration was correlated with significantly lowered circulating NA levels. These results correlated with reduced blood pressures including, systolic, diastolic and mean arterial pressure in both positions. 48 Furthermore, reduced blood pressures have also been correlated with various blood flow parameters including femoral-carotid pulse wave velocity (PWV) and pulse wave propagation time (PWPT). Pulse wave velocity is clinically used to provide a measure of arterial stiffness, is inversely related to arterial distensibility and is a clinical characteristic in the development of hypertension. Melatonin decreased PWV and increased PWPT. Several studies have shown that arterial stiffness depends on a number of factors including sympathetic stimulation. Therefore, given that the measurable changes in blood flow properties were acute, the effects were concluded to be attributed to an inhibitory effect on sympathetic activity. 87 Combined, the results argue that the effects of melatonin are associated with sympathetic inhibition. However, melatonin may not only inhibit sympathetic activity, but it may also stimulate parasympathetic activity.
| Parasympathetic activation
As we age, acetylcholine (the predominant neurotransmitter associated with parasympathetic activity) synthesis becomes impaired. In an aging model, Brusco et al 107 identified that older rats receiving exogenous melatonin treatment had partial restoration of acetylcholine synthesis as compared to older control groups not receiving treatment. 107 Moreover, in urethane-anaesthetized rats, melatonin reduced mean arterial pressure, heart rate and serotonin levels.
Interestingly, melatonin-induced bradycardia was abolished following bilateral vagotomy. The results demonstrate that melatonin decreases serotonin release and suggest that melatonin is involved in parasympathetic stimulation, which leads to hypotension and bradycardia in rats. 108 Lastly, in humans, melatonin administration increased parasympathetic parameters of heart rate variability including R-R interval, Root Mean Square of the Successive Differences (RMSSD) and high frequency and decreased the low frequency: high frequency ratio and blood pressure in the supine position. 52 Overall, an abundance of evidence exists that supports the role of melatonin in blood pressure regulation. The exact mechanisms by which melatonin elicits its hypotensive effects, particularly in humans, are likely multi-faceted and are still under investigation.
Endothelial-dependent vasodilation, anti-oxidant defense mechanisms and autonomic regulation are among the most current mechanisms suggested to be involved in eliciting the hypotensive effects of melatonin (Figure 3 ). While the potential anti-hypertensive and protective effect of melatonin in hypertension have not been fully elucidated, there is a growing source of evidence to strongly support the aforementioned mechanisms. Overall, these data indicate a clear potential for melatonin to be an effective adjunct anti-hypertensive agent.
| IMPLI C ATI ON S FOR SUPINE HYPERTENS ION IN AUTONOMIC DYS FUN C TION
Given the considerable association between melatonin production and secretion, the influence of the sympathetic nervous system and the potential mechanism regarding sympathetic inhibition, future studies investigating melatonin in persons with autonomic failure would warrant interest. A cardinal feature of autonomic failure includes neurogenic orthostatic hypotension (NOH), which is characterized by a drop in systolic blood pressure ≥ 30 mm Hg due to dysfunction of the sympathetic nervous system. 109 Paradoxically, approximately 50% of NOH patients can also have associated supine/nocturnal hypertension as a result of residual, uncontrolled sympathetic nerve activity. [110] [111] [112] Currently there are no FDA or F I G U R E 3 Summary flowchart highlighting the most prominent potential patho-mechanisms of melatonin. cGMP, cyclic guanosine monophosphate; CAT, catalase; GABA, gamma aminobutyric acid; GSH, glutathione peroxidase; HF, high frequency; HRV, heart rate variability; LF, low frequency; NO, nitric oxide; NOS, nitric oxide synthase; RMSSD, root mean square of the successive differences; RNS, reactive nitrogen species; ROS, Reactive oxygen species; SOD, superoxide dismutase Health Canada approved anti-hypertensive agents for use in this unique clinical population as attempts at improving one blood pressure problem will often worsen the other. Therefore, investigating the effects of exogenous melatonin in patients with nocturnal hypertension secondary to autonomic failure may not only provide useful information regarding the clinical utility of melatonin in a unique patient population, but could also substantiate sympathetic inhibition as a mechanism of melatonin if compared between autonomic failure patients with and without residual sympathetic nerve activity.
Cross-section studies suggest the clinical significance of supine hypertension is equivalent to that of essential hypertension, with similar levels of target end-organ damage, such as left ventricular hypertrophy and renal impairment, 113, 114 and equivalent risk for heart failure, stroke and cerebral haemorrhage following a hypertensive crisis. 115, 116 Given the reported positive impact of chronotherapy in reducing cardiovascular risk in hypertensive patients, 117 it does lend some evidence to suggest that even a small reduction in nocturnal blood pressure could serve to have important clinical implications for patients with nocturnal hypertension associated with autonomic dysfunction. 
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